Search Results
Apr 28, 2026, 12:00 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX).
More news about: Glancy Prongay Wolke & Rotter LLP
Apr 28, 2026, 09:00 ET IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
Apr 27, 2026, 20:33 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 27, 2026, 15:50 ET ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Apr 24, 2026, 22:00 ET ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026Basis: ImmunityBio shares fell on FDA warning letter
More news about: Kahn Swick & Foti, LLC
Apr 24, 2026, 16:40 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 26, 2026 (LEAD PLAINTIFF DEADLINE) TO
More news about: Law Offices of Howard G. Smith
Apr 23, 2026, 17:54 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected], Inc. (IBRX) Securities Class Action: ImmunityBio
More news about: Hagens Berman Sobol Shapiro LLP
Apr 23, 2026, 09:00 ET IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt
Securities Class Action Services' Top 50 Report.Frequently Asked Questions About the IBRX LawsuitQ: Who is eligible to join the IBRX investor lawsuit? A: Investors who purchased IBRX stock or securities between January 19, 2026 and March 24, 2026 and suffered financial losses
More news about: SueWallSt.com
Apr 22, 2026, 17:07 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: THE ROSEN LAW FIRM, P. A.
Apr 22, 2026, 09:00 ET IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky
of artificial inflation that had entered IBRX shares beginning January 19, 2026 when the Executive Chairman appeared on a nationally broadcast podcast and made sweeping claims about ANKTIVA's capabilities. According to the action, shareholders who purchased IBRX stock at prices inflated by these allegedly
More news about: Levi & Korsinsky, LLP
Apr 21, 2026, 15:17 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 21, 2026, 13:00 ET ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Apr 21, 2026, 10:14 ET IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 21, 2026, 09:00 ET IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
Apr 20, 2026, 03:09 ET ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during the class period listed are encouraged
More news about: DJS Law Group LLP
Apr 17, 2026, 22:00 ET ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive
More news about: ClaimsFiler
Apr 17, 2026, 18:46 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: THE ROSEN LAW FIRM, P. A.
Apr 17, 2026, 08:22 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immunitybio-inc-of-class-action-lawsuit-and-upcoming-deadlines--ibrx-302744202.htmlSOURCE
More news about: Pomerantz LLP
Apr 16, 2026, 09:58 ET IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 16, 2026, 09:05 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until Tuesday, May 26, 2026
More news about: Robbins Geller Rudman & Dowd LLP
Apr 16, 2026, 09:00 ET IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt
April 16, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: SueWallSt.com
Apr 15, 2026, 21:19 ET Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action
LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.
More news about: Robbins LLP
Apr 15, 2026, 17:59 ET IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Apr 15, 2026, 14:59 ET INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP